It had posted net profit of Rs 65.93 crore in the same quarter of the 2013-14 fiscal, Alembic Pharma said in a filing to the BSE.
Net sales during the period under review stood at Rs 514.9 crore as against Rs 486.74 crore in the year-ago quarter, the company said.
Also Read
International generic formulation posted a growth of 3 per cent at Rs 133.3 crore as compared to Rs 129.6 crore a year-ago.
During the quarter, the company filed one abbreviated new drug application (ANDAs) and received approval for one. It also filed two drug master file (DMF) applications during the period.
Alembic Pharmaceuticals stock closed over 11 per cent down at Rs 429.55 apiece on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)